Newswise — LOS ANGELES – When a soldier sustains a traumatic eye injury on the battlefield, any delay in treatment may lead to permanent vision loss. With medical facilities potentially far away and no existing tools to prevent deterioration, medics are in a high-stakes race against the clock.
A multidisciplinary team of scientists and engineers at USC are close to solving the problem. They have developed a reversible, temperature-sensitive temporary seal that changes from a fluid to a super-strong semi-solid when applied to the eye. When the patient is ready for surgery to permanently close the injury, doctors can remove the seal by adding cool water.
Results of the study were published on Dec. 6 in Science Translational Medicine.
“If you look at historical data over the last several decades, the rate of war-related ocular injuries has steadily increased from a fraction of a percent to as high as 10 to 15 percent. Some of that can be attributed to changes in warfare, especially with the use of improvised explosive devices,” says corresponding author John Whalen, assistant professor of research ophthalmology at the USC Roski Eye Institute and member of the USC Institute for Biomedical Therapeutics. “When the Department of Defense asked the scientific community to develop novel approaches to treating ocular injuries, we immediately thought of an advanced material we had previously worked with as a possible adhesive for a retinal implant.”
The study represents the latest development from the USC Institute for Biomedical Therapeutics, which fosters collaborations between scientists at the Keck School of Medicine of USC, chemists at the USC Dornsife College of Letters, Arts and Sciences and engineers at the USC Viterbi School of Engineering. USC has made research in convergent bioscience and biotechnology a priority to address health issues across the lifespan through the development of new diagnostic tools, treatments and biomedical devices.
A custom fit
The material the group was working with for retinal implants was a hydrogel called PNIPAM, poly(N-isopropylacrylamide), which had a unique attribute that made it a natural fit for this application: When cooled, the hydrogel became a liquid for easy application, and when heated, it became a viscous semi-solid with strong adhesion. All that was needed was some tailoring.
“Since the initial hydrogel’s transition temperature was very close to the temperature of the human eye, we had to modify its properties to ensure that it would form a solid seal as soon as the gel was applied to the eye by a soldier or medic,” says lead author Niki Bayat, a doctoral candidate in the Mork Family Department of Chemical Engineering and Materials Science at the USC Viterbi School. “Providing a perfect, yet reversible seal, the smart hydrogel shows promise for the next generation of tissue adhesives.”
When an ophthalmologist is ready to repair the eye, the hydrogel can be extracted by applying cool water and converting it back to a less adhesive state.
The research team also developed a special syringe for the hydrogel that would be easy to use on the front lines and capable of quickly cooling the hydrogel before application. The syringe has a cooling chamber filled with calcium ammonium nitrate crystals — the type that are used in instant ice cold packs. By adding water to the chamber, the crystals activate and cool the hydrogel to operating temperatures within 30 seconds.
“We were able to optimize the delivery device so that it not only rapidly cools the hydrogel but also holds it at that temperature, giving users a 10-minute window to fill penetrations in the eye,” Whalen says. “It’s very simple to use — almost like caulking a bathroom seal.”
The customized seal and delivery device will also reduce the amount of time it takes to close penetrating eye injuries overall.
“This temporary intervention could decrease repair time from 30 minutes or longer to less than five minutes, freeing up valuable time for first responders and trauma units,” says principal investigator Mark Humayun, university professor of ophthalmology and co-director of the USC Roski Eye Institute and director of the USC Institute for Biomedical Therapeutics.
To establish the material’s efficacy, a rabbit model was used. Results showed that when applied to eyes with penetrating injuries, the hydrogel improved pressure within the eye, which may be critical for preventing retinal detachment that can ultimately lead to vision loss. There also was no evidence of inflammation or infection for up to four weeks of use. The researchers hope to initiate clinical safety testing in humans in 2019.
Whalen envisions applications for the hydrogel that go beyond the battlefield.
“First responders at a mass casualty incident could deploy the hydrogel while patients wait for their injuries to be completely repaired by an ocular surgeon in appropriate microsurgical facilities,” he says. “It could also be useful in ERs in rural areas where there isn’t an eye center with such capabilities nearby. It may even have potential for temporarily treating gunshot wounds.”
This study was supported by the Office of the Assistant Secretary of Defense for Health Affairs under award number W81XWH12-1-0314 and the National Institutes of Health under award number UL1TR000130. 0.115 percent of the study’s costs were covered by a $35,986,454, four-year National Institutes of Health grant awarded to Thomas Buchanan in 2012. The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Department of Defense or the National Institutes of Health.
About the USC Roski Eye Institute
The USC Roski Eye Institute, part of the Keck Medicine of USC university-based medical enterprise, has been a leader in scientific research and innovative clinical treatments for more than 40 years. Ranked No. 2 in National Eye Institute (NEI) research grants for academically based ophthalmology departments and nationally ranked in U.S. News & World Report’s annual “Best Hospitals” issue for more than 24 years, the USC Roski Eye Institute is headquartered in Los Angeles with clinics in Arcadia, Beverly Hills and Pasadena. Faculty physicians are also the exclusive ophthalmic doctors affiliated with Los Angeles County + USC Medical Center (LAC+USC) and Children’s Hospital Los Angeles (CHLA).
For more information, go to eye.keckmedicine.org.
About the USC Viterbi School of Engineering
Engineering Studies began at the University of Southern California in 1905. Nearly a century later, the Viterbi School of Engineering received a naming gift in 2004 from alumnus Andrew J. Viterbi, inventor of the Viterbi algorithm that is now key to cell phone technology and numerous data applications. One of the school’s guiding principles is engineering +, a term coined by current Dean Yannis C. Yortsos, to use the power of engineering to address the world’s greatest challenges. USC Viterbi is ranked among the top graduate programs in the world and enrolls more than 6,500 undergraduate and graduate students taught by 185 tenured and tenure-track faculty, with 73 endowed chairs and professorships.
Journal Link: Science Translational Medicine Grant No Link: Office of the Assistant Secretary of Defense for Health Affairs Grant No Link: National Institutes of Health
MEDIA CONTACTRegister for reporter access to contact details
Science Translational Medicine; Office of the Assistant Secretary of Defense for Health Affairs; National Institutes of Health